Want to see KR:293480 full AI Analyst Report?

Hana Pharm Co., Ltd. (293480) Price & Analysis

― Followers

293480 Stock Chart & Stats

₩8170.00

₩0.00(0.00%)

Oct 28, 2026

―

Day’s Range― - ―

52-Week Range₩8,050.00 - ₩11,930.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)15.11K

Market Cap

₩141.34B

Enterprise Value₩207.31B

Total Cash (Recent Filing)₩17.28B

Total Debt (Recent Filing)₩68.84B

Price to Earnings (P/E)8.3

Beta0.08

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield3.18%

Share Statistics

EPS (TTM)982.93

Shares Outstanding17,772,945

10 Day Avg. Volume18,984

30 Day Avg. Volume15,108

Financial Highlights & Ratios

PEG Ratio-0.38

Price to Book (P/B)0.64

Price to Sales (P/S)0.83

P/FCF Ratio-10.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1,247

Revenue Forecast (FY)₩257.30B

Bulls Say, Bears Say

Bulls Say

Strong Revenue GrowthThe sharp TTM revenue increase indicates substantial expansion in the company’s pharmaceutical sales base and commercial reach. If the growth is sustained, it can provide operating leverage, support reinvestment in drug development and commercialization, and strengthen Hana Pharm’s position in its target markets over the coming quarters.

Healthy Operating MarginsRobust gross profitability and positive operating margins show that Hana Pharm’s products generate meaningful economic value after production costs. This profitability provides a foundation for funding operations and investment, while giving the company some resilience if revenue growth moderates over the next several quarters.

Conservative LeverageLow-to-moderate leverage and steadily expanding equity indicate a relatively flexible balance sheet. Compared with a more highly indebted structure, this gives Hana Pharm greater capacity to absorb operating volatility, maintain investment, and manage funding needs while pursuing pharmaceutical growth opportunities.

Bears Say

Deeply Negative Free Cash FlowPersistent negative free cash flow means reported profitability is not currently translating into cash available for debt reduction, dividends, or discretionary investment. If the shortfall continues, Hana Pharm may need additional financing or must moderate expansion spending, increasing execution and funding risk.

Weak Cash ConversionOperating cash flow that remains far below net income signals weak conversion of accounting earnings into internally generated funds. This reduces the quality and flexibility of current earnings, limits self-funded growth, and leaves the company more exposed if capital needs remain elevated over the next several months.

Profitability Efficiency PressureThe decline in net margin from prior years shows that rapid revenue expansion has not been accompanied by equally strong bottom-line conversion. Combined with only moderate returns on equity, this suggests rising costs, mix effects, or investment demands could continue to constrain profitability quality and capital efficiency.

293480 FAQ

What was Hana Pharm Co., Ltd.’s price range in the past 12 months?

Hana Pharm Co., Ltd. lowest stock price was ₩8050.00 and its highest was ₩11930.00 in the past 12 months.

What is Hana Pharm Co., Ltd.’s market cap?

Hana Pharm Co., Ltd.’s market cap is ₩141.34B.

When is Hana Pharm Co., Ltd.’s upcoming earnings report date?

Hana Pharm Co., Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 20 days.

How were Hana Pharm Co., Ltd.’s earnings last quarter?

Hana Pharm Co., Ltd. released its earnings results on Aug 14, 2026. The company reported ₩476.776 earnings per share for the quarter.

Is Hana Pharm Co., Ltd. overvalued?

According to Wall Street analysts Hana Pharm Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hana Pharm Co., Ltd. pay dividends?

Hana Pharm Co., Ltd. pays a Annually dividend of ₩260 which represents an annual dividend yield of 3.18%. See more information on Hana Pharm Co., Ltd. dividends here

What is Hana Pharm Co., Ltd.’s EPS estimate?

Hana Pharm Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hana Pharm Co., Ltd. have?

Hana Pharm Co., Ltd. has 17,772,945 shares outstanding.

What happened to Hana Pharm Co., Ltd.’s price movement after its last earnings report?

Hana Pharm Co., Ltd. reported an EPS of ₩476.776 in its last earnings report. Following the earnings report the stock price went up 1.814%.

Which hedge fund is a major shareholder of Hana Pharm Co., Ltd.?

Currently, no hedge funds are holding shares in KR:293480

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Hana Pharm Co., Ltd.

Hana Pharm Co., Ltd. is a pharmaceutical enterprise that manufactures and supplies a diverse range of medicinal goods to both domestic South Korean and international markets. Its comprehensive product line covers various therapeutic categories, such as anesthetics, potent narcotic pain relievers, anti-nausea agents, muscle relaxants, and treatments targeting the cardiovascular, endocrine, gastrointestinal, respiratory, and central nervous systems. Furthermore, the company offers antibiotics, dermatological preparations, urological medications, osteoporosis therapies, and medications for pain, fever, and inflammation. The firm was established in 1958 and has its corporate headquarters located in Seoul, South Korea.